Patents by Inventor Sarah Schmidt Grant

Sarah Schmidt Grant has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
    Publication number: 20240058315
    Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: August 8, 2023
    Publication date: February 22, 2024
    Inventors: Sarah Schmidt GRANT, Bettina HEDERER, Thomas LANGENICKEL, David J. ROWLANDS, Robert Martin STRIETER, Xianbin TIAN
  • METHODS OF TREATING AN INFLAMMATORY OR OBSTRUCTIVE AIRWAY DISEASE USING ANTI-TSLP ANTIBODY
    Publication number: 20230082287
    Abstract: The present disclosure relates to methods, treatment regimens, uses, kits, compositions and medicaments for treating an inflammatory or obstructive airway disease, such as asthma, including severe asthma, or COPD, by employing an anti-TSLP antibody or anti-TSLP antibody fragment.
    Type: Application
    Filed: January 28, 2021
    Publication date: March 16, 2023
    Inventors: Ankur AJMERA, Jürgen DEDERICHS, Sarah Schmidt GRANT, Kristin HENSON, Monish JAIN, Sandro PAGANI, Yinuo PANG, Marianna ROWLANDS
  • Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
    Publication number: 20200383960
    Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat bronchiectasis, cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: June 8, 2020
    Publication date: December 10, 2020
    Inventors: Sarah Schmidt GRANT, Bettina HEDERER, Thomas LANGENICKEL, David J. ROWLANDS, Robert Martin STRIETER, Xianbin TIAN
  • Methods of selectively treating asthma using IL-17 antagonists
    Patent number: 10676522
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating asthma, such as severe asthma, by employing IL-17 antagonists to a patient population defined by serum concentration of IgE and optionally also an eosinophil count in peripheral blood.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: June 9, 2020
    Assignee: NOVARTIS AG
    Inventors: Sarah Schmidt Grant, Shamsah Kazani, Edward Khokhlovich, Jason Laramie, Robert Martin Strieter, Tricia Ann Thornton-Wells
  • METHODS OF SELECTIVELY TREATING ASTHMA USING IL-17 ANTAGONISTS
    Publication number: 20180319881
    Abstract: The disclosure relates to methods, treatment regimens, uses, kits and therapies for treating asthma, such as severe asthma, by employing IL-17 antagonists to a patient population defined by serum concentration of IgE and optionally also an eosinophil count in peripheral blood.
    Type: Application
    Filed: May 3, 2018
    Publication date: November 8, 2018
    Inventors: Sarah Schmidt Grant, Shamsah Kazani, Edward Khokhlovich, Jason Laramie, Robert Martin Strieter, Tricia Ann Thornton-Wells